Emergence of raltegravir-resistant HIV-1 in the central nervous system

被引：7
|
作者：
Watanabe, K. [1 ]
Honda, M. [1 ]
Watanabe, T. [1 ]
Tsukada, K. [1 ]
Teruya, K. [1 ]
Kikuchi, Y. [1 ]
Oka, S. [1 ]
Gatanaga, H. [1 ]
机构：
[1] Natl Ctr Global Hlth & Med, AIDS Clin Ctr, Shinjuku Ku, Tokyo 1628655, Japan
来源：
INTERNATIONAL JOURNAL OF STD & AIDS | 2010年 / 21卷 / 12期
关键词：
integrase; resistant; cerebrospinal fluid; Q148R; HIV; raltegravir; CEREBROSPINAL-FLUID; INFECTION;
D O I：
10.1258/ijsa.2009.009283
中图分类号：
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号：
100102 ;
摘要：
Integrase inhibitor-resistant HIV-1 was detected in the cerebrospinal fluid, but not in the plasma of a 42-year-old man with HIV encephalopathy treated with a raltegravir (RAL)-containing regimen. Raltegravir resistance may develop in the central nervous system when the virus is already multi-drug resistant because of different penetration into cerebrospinal fluid of individual antiretroviral agents.
引用
收藏
页码：840 / 841
页数：2
相关论文
共 50 条
  • [31] Is the Central Nervous System Reservoir a Hurdle for an HIV Cure?
    Mohammadzadeh, Nazanin
    Chomont, Nicolas
    Estaquier, Jerome
    Cohen, Eric A.
    Power, Christopher
    VIRUSES-BASEL, 2023, 15 (12):
  • [32] Central Nervous System Compartmentalization of HIV-1 Subtype C Variants Early and Late in Infection in Young Children
    Sturdevant, Christa Buckheit
    Dow, Anna
    Jabara, Cassandra B.
    Joseph, Sarah B.
    Schnell, Gretja
    Takamune, Nobutoki
    Mallewa, Macpherson
    Heyderman, Robert S.
    Van Rie, Annelies
    Swanstrom, Ronald
    PLOS PATHOGENS, 2012, 8 (12)
  • [33] Pathogenesis of HIV in the central nervous system
    Valcour V.
    Sithinamsuwan P.
    Letendre S.
    Ances B.
    Current HIV/AIDS Reports, 2011, 8 (1) : 54 - 61
  • [34] Treatment Intensification Has no Effect on the HIV-1 Central Nervous System Infection in Patients on Suppressive Antiretroviral Therapy
    Yilmaz, Aylin
    Verhofstede, Chris
    D'Avolio, Antonio
    Watson, Victoria
    Hagberg, Lars
    Fuchs, Dietmar
    Svennerholm, Bo
    Gisslen, Magnus
    JAIDS-JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES, 2010, 55 (05) : 590 - 596
  • [35] Usefulness of Integrase resistance testing in proviral HIV-1 DNA in patients with Raltegravir prior failure
    Jose Ángel Fernández-Caballero
    Natalia Chueca
    Marta Álvarez
    María Dolores Mérida
    Josefa López
    José Antonio Sánchez
    David Vinuesa
    María Ángeles Martínez
    José Hernández
    Federico García
    BMC Infectious Diseases, 16
  • [36] EXPRESSION OF HIV-1 IN THE CEREBROSPINAL-FLUID DETECTED BY THE POLYMERASE CHAIN-REACTION AND ITS CORRELATION WITH CENTRAL-NERVOUS-SYSTEM DISEASE
    GOSWAMI, KK
    MILLER, RF
    HARRISON, MJ
    HAMEL, DJ
    DANIELS, RS
    TEDDER, RS
    AIDS, 1991, 5 (07) : 797 - 803
  • [37] Diketoacid Inhibitors of HIV-1 Integrase: From L-708,906 to Raltegravir and Beyond
    Beare, K. D.
    Coster, M. J.
    Rutledge, P. J.
    CURRENT MEDICINAL CHEMISTRY, 2012, 19 (08) : 1177 - 1192
  • [38] Cerebrospinal fluid analysis in the HIV infection and compartmentalization of HIV in the central nervous system
    de Almeida, Sergio Monteiro
    ARQUIVOS DE NEURO-PSIQUIATRIA, 2015, 73 (07) : 624 - 629
  • [39] Update on Central Nervous System Effects of the Intersection of HIV-1 and SARS-CoV-2
    Ferron F. Ocampo
    Pathariya Promsena
    Phillip Chan
    Current HIV/AIDS Reports, 2023, 20 : 345 - 356
  • [40] A Review of Raltegravir and its Use in HIV-1 Infection
    Boesecke, Christoph
    Gelgor, Linda
    CLINICAL MEDICINE INSIGHTS-THERAPEUTICS, 2009, 1 : 1159 - 1171
12345